Dementia, Lewy Body

Categories: Genetic diseases, Rare diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Dementia, Lewy Body

MalaCards integrated aliases for Dementia, Lewy Body:

Name: Dementia, Lewy Body 53 24 13
Lewy Body Dementia 53 12 49 24 50 71 36 28 14
Lewy Body Disease 12 49 24 51 40 41 69
Diffuse Lewy Body Disease 53 12 49 24 71
Dementia with Lewy Bodies 12 72 24 50
Dlb 53 49 24 71
Autosomal Dominant Diffuse Lewy Body Disease 49 69
Diffuse Lewy Body Disease with Gaze Palsy 71
Lewy Body Variant of Alzheimer Disease 71
Lewy Body Dementia, Susceptibility to 53
Senile Dementia of the Lewy Body Type 12
Dementia of the Lewy Body Type 24
Lewy Body Type Senile Dementia 71
Dysphasic Dementia Hereditary 71
Cortical Lewy Body Disease 71
Dementia Lewy Body 71
Lewy Bodies 28
Lbd 24



autosomal dominant

onset in the sixth or seventh decades
phenotypic overlap with parkinson disease
allelic disorder to parkinson disease-1 (park1, )


dementia, lewy body:
Inheritance autosomal dominant inheritance


External Ids:

OMIM 53 127750
Disease Ontology 12 DOID:12217
ICD10 32 G31.83
ICD9CM 34 331.82
MeSH 41 D020961
NCIt 46 C84826
KEGG 36 H00066

Summaries for Dementia, Lewy Body

NINDS : 50 Dementia with Lewy bodies (DLB) is one of the most common types of progressive dementia. The central features of DLB include progressive cognitive decline, “fluctuations” in alertness and attention, visual hallucinations, and parkinsonian motor symptoms, such as slowness of movement, difficulty walking, or rigidity.  People may also suffer from depression.  The symptoms of DLB are caused by the build-up of Lewy bodies – accumulated bits of alpha-synuclein protein -- inside the nuclei of neurons in areas of the brain that control particular aspects of memory and motor control.  Researchers don’t know exactly why alpha-synuclein accumulates into Lewy bodies or how Lewy bodies cause the symptoms of DLB, but they do know that alpha-synuclein accumulation is also linked to Parkinson's disease, multiple system atrophy, and several other disorders, which are referred to as the "synucleinopathies." The similarity of symptoms between DLB and Parkinson’s disease, and between DLB and Alzheimer’s disease, can often make it difficult for a doctor to make a definitive diagnosis. In addition, Lewy bodies are often also found in the brains of people with Parkinson's and Alzheimer’s diseases.  These findings suggest that either DLB is related to these other causes of dementia or that an individual can have both diseases at the same time.  DLB usually occurs sporadically, in people with no known family history of the disease. However, rare familial cases have occasionally been reported.

MalaCards based summary : Dementia, Lewy Body, also known as lewy body dementia, is related to corticobasal degeneration and parkinson disease, late-onset, and has symptoms including dementia, parkinsonism and delusions. An important gene associated with Dementia, Lewy Body is SNCA (Synuclein Alpha), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Circadian entrainment. The drugs Armodafinil and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and colon, and related phenotypes are homeostasis/metabolism and behavior/neurological

OMIM : 53 Dementia with Lewy bodies (DLB) is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Pathologically, Lewy bodies are present in a pattern more widespread than usually observed in Parkinson disease (see PD; 168600). Alzheimer disease (AD; 104300)-associated pathology and spongiform changes may also be seen (McKeith et al., 1996; Mizutani, 2000; McKeith et al., 2005). (127750)

UniProtKB/Swiss-Prot : 71 Dementia Lewy body: A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.

NIH Rare Diseases : 49 Lewy body dementia is one of the most common forms of progressive dementia. People affected by this condition may experience a variety of symptoms such as changes in alertness and attention; hallucinations; problems with movement and posture; muscle stiffness; confusion; and/or memory loss. Although the exact cause of Lewy body dementia is poorly understood, symptoms are thought to result when clumps of a protein called alpha-synuclein ("Lewy bodies") accumulate in the brain. Lewy body dementia usually occurs sporadically in people with no family history of the condition. Rarely, more than one family member may be affected. There is currently no cure for Lewy body dementia; however, medications may be available to help manage the associated symptoms. Last updated: 11/5/2015

MedlinePlus : 40 Lewy body disease is one of the most common causes of dementia in the elderly. Dementia is the loss of mental functions severe enough to affect normal activities and relationships. Lewy body disease happens when abnormal structures, called Lewy bodies, build up in areas of the brain. The disease may cause a wide range of symptoms, including Changes in alertness and attention Hallucinations Problems with movement and posture Muscle stiffness Confusion Loss of memory Lewy body disease can be hard to diagnose, because Parkinson's disease and Alzheimer's disease cause similar symptoms. Scientists think that Lewy body disease might be related to these diseases, or that they sometimes happen together. Lewy body disease usually begins between the ages of 50 and 85. The disease gets worse over time. There is no cure. Treatment focuses on drugs to help symptoms. NIH: National Institute of Neurological Disorders and Stroke

Genetics Home Reference : 24 Dementia with Lewy bodies is a nervous system disorder characterized by a decline in intellectual function (dementia), a group of movement problems known as parkinsonism, visual hallucinations, sudden changes (fluctuations) in behavior and intellectual ability, and acting out dreams while asleep (REM sleep behavior disorder). This condition typically affects older adults, most often developing between ages 50 and 85. The life expectancy of individuals with dementia with Lewy bodies varies; people typically survive about 5 to 7 years after they are diagnosed.

Disease Ontology : 12 A dementia and a synucleinopathy that is characterized by the development of abnormal proteinaceous (alpha-synuclein) cytoplasmic inclusions, called Lewy bodies, throughout the brain that results in progressive decline in mental abilities.

Wikipedia : 72 Dementia with Lewy bodies (DLB) is a type of dementia that worsens over time. Additional symptoms may... more...

Related Diseases for Dementia, Lewy Body

Diseases related to Dementia, Lewy Body via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Related Disease Score Top Affiliating Genes
1 corticobasal degeneration 31.9 GBA LRRK2 MAPT RPS27A
2 parkinson disease, late-onset 30.1 ACHE APOE APP BCHE CYP2D6 GBA
3 dementia 29.4 ACHE APOE APP GBA MAPT PARK7
4 alzheimer disease 29.3 ACHE APOE APP BCHE MAOB MAPT
5 frontotemporal dementia 29.1 ACHE APOE APP BCHE LRRK2 MAPT
6 parkinson disease 1, autosomal dominant 11.9
7 parkinson disease 4, autosomal dominant 11.8
8 myoclonic epilepsy of lafora 11.1
9 hereditary late-onset parkinson disease 10.5 GBA LRRK2 SNCA
10 senile plaque formation 10.5 APOE APP
11 posterior cortical atrophy 10.5 APOE MAPT
12 dysautonomia 10.5 PRKN SNCA SNCAIP
13 genetic prion diseases 10.5 APOE PRNP
14 familial idiopathic basal ganglia calcification 10.5 APOE APP MAPT
15 early-onset familial alzheimer disease 10.4 APP MAPT SNCA
16 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 10.4 MAPT RPS27A
17 akinetic mutism 10.4 MAPT PRNP SLC6A3
18 semantic dementia 10.4 APOE MAPT RPS27A
19 neuronal intranuclear inclusion disease 10.4 MAPT RPS27A SNCA
20 cocaine abuse 10.4 SLC18A2 SLC6A3 SNCA
21 postencephalitic parkinson disease 10.4 LRRK2 MAOB MAPT SNCA
22 parkinson disease 10 10.4 LRRK2 PARK7 PRKN SNCA
23 parkinson disease 2, autosomal recessive juvenile 10.4 LRRK2 PARK7 PRKN SNCA
24 essential tremor 10.4 LRRK2 PRKN SLC6A3 SNCA
25 hypoganglionosis 10.4 ACHE TH
26 hydrocephalus, normal-pressure 10.4 ADAMTS2 APOE MAPT
27 communicating hydrocephalus 10.3 ADAMTS2 APOE MAPT
28 neurodegeneration with brain iron accumulation 2a 10.3 APP RPS27A SNCB
29 binswanger's disease 10.3 ACHE APOE APP MAPT
30 alzheimer disease 2 10.3 APOE APP BCHE MAPT
31 perry syndrome 10.3 SLC18A2 SLC6A3 SNCA TH
32 prion disease 10.3 APP MAPT PRNP
33 tremor 10.3 GBA LRRK2 MAPT PRKN SNCA
34 machado-joseph disease 10.3 RPS27A SLC6A3 SNCA
35 gait apraxia 10.3 APOE APP
36 cerebral hemorrhage 10.3 APP PRNP
37 cerebral amyloid angiopathy, cst3-related 10.3 APOE APP MAPT PRNP
38 pure autonomic failure 10.3 ACHE MAOB SNCA TH
39 early-onset parkinson disease 10.3 GBA LRRK2 PARK7 PRKN SNCA
40 creutzfeldt-jakob disease 10.3 APOE MAPT PRNP
41 agraphia 10.2 ACHE BCHE MAPT PRNP
42 inclusion body myositis 10.2 APOE APP MAPT RPS27A
43 parkinson disease 15, autosomal recessive early-onset 10.2 LRRK2 PARK7 PRKN SNCA TH
44 pick disease of brain 10.2 APOE APP MAPT RPS27A SNCA
45 rem sleep behavior disorder 10.2 ACHE LRRK2 RPS27A SLC6A3 SNCA
46 restless legs syndrome 10.2 MAOB PRKN SLC6A3 SNCA TH
47 parkinson disease 3, autosomal dominant 10.1 LRRK2 MAPT PARK7 PRKN SNCA SNCAIP
48 leukoencephalopathy, hereditary diffuse, with spheroids 10.1 APP MAPT PRNP RPS27A SNCA
49 alcohol dependence 10.1 MAOB SLC18A2 SLC6A3 SNCA
50 glucocorticoid resistance, generalized 10.1

Graphical network of the top 20 diseases related to Dementia, Lewy Body:

Diseases related to Dementia, Lewy Body

Symptoms & Phenotypes for Dementia, Lewy Body

Symptoms via clinical synopsis from OMIM:

Neurologic Central Nervous System:
visual hallucinations
fluctuations in consciousness
progressive dementia

Clinical features from OMIM:


Human phenotypes related to Dementia, Lewy Body:

# Description HPO Frequency HPO Source Accession
1 dementia 31 HP:0000726
2 parkinsonism 31 HP:0001300
3 delusions 31 HP:0000746
4 visual hallucinations 31 HP:0002367
5 fluctuations in consciousness 31 HP:0007159

UMLS symptoms related to Dementia, Lewy Body:

sleeplessness, vertigo/dizziness, hallucinations, visual, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, back pain

MGI Mouse Phenotypes related to Dementia, Lewy Body:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 ACHE APOE APP BCHE GBA LRRK2
2 behavior/neurological MP:0005386 10.37 GBA LRRK2 MAOB MAPT PARK7 PRKN
3 growth/size/body region MP:0005378 10.34 TH ACHE ADAMTS2 APOE APP GBA
4 cellular MP:0005384 10.32 APOE APP GBA LRRK2 MAOB MAPT
5 mortality/aging MP:0010768 10.28 ACHE APOE APP SLC6A3 SNCA SNCB
6 nervous system MP:0003631 10.24 MAOB MAPT PARK7 PRKN PRNP SLC18A2
7 integument MP:0010771 10.2 PRNP SLC6A3 SNCA TH APOE APP
8 no phenotypic analysis MP:0003012 10.02 ACHE APOE APP LRRK2 MAPT PRKN
9 muscle MP:0005369 10.01 ACHE APOE APP MAPT PRKN PRNP
10 normal MP:0002873 10 ADAMTS2 APP GBA LRRK2 MAPT PRKN
11 respiratory system MP:0005388 9.7 ACHE ADAMTS2 APOE GBA LRRK2 PRKN
12 skeleton MP:0005390 9.61 ADAMTS2 APOE GBA LRRK2 PRKN PRNP
13 taste/olfaction MP:0005394 9.02 APOE MAPT SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Dementia, Lewy Body

Drugs for Dementia, Lewy Body (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Armodafinil Approved, Investigational Phase 4 112111-43-0
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
Acetaminophen Approved Phase 4 103-90-2 1983
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
Iodine Approved, Investigational Phase 4 7553-56-2 807
Corticosterone Experimental Phase 4 50-22-6 5753
10 Central Nervous System Stimulants Phase 4
11 Cytochrome P-450 CYP3A Inducers Phase 4
12 Wakefulness-Promoting Agents Phase 4
13 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
15 Cholinergic Agents Phase 4,Phase 3,Phase 2
16 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2
17 Nootropic Agents Phase 4,Phase 3,Phase 2
18 Antiparkinson Agents Phase 4,Phase 3,Phase 2
19 Excitatory Amino Acid Antagonists Phase 4,Phase 2
20 Excitatory Amino Acids Phase 4,Phase 2
21 Analgesics Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Analgesics, Opioid Phase 4
24 Antipyretics Phase 4
25 Central Nervous System Depressants Phase 4,Phase 3
26 Narcotic Antagonists Phase 4
27 Narcotics Phase 4
28 Peripheral Nervous System Agents Phase 4,Phase 3
29 Pharmaceutical Solutions Phase 4
30 cadexomer iodine Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Fluorodeoxyglucose F18 Phase 4
33 Calamus Nutraceutical Phase 4
Galantamine Approved Phase 3 357-70-0 9651
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
36 Autonomic Agents Phase 3
37 Protective Agents Phase 3
38 Antipsychotic Agents Phase 3
39 Psychotropic Drugs Phase 3
Serotonin Phase 3 50-67-9 5202
41 Serotonin Agents Phase 3
42 Tranquilizing Agents Phase 3
43 Dopamine agonists Phase 2,Phase 1
Acetylcholine Approved 51-84-3 187
Rivastigmine Approved, Investigational 123441-03-2 77991
Acetylcysteine Approved, Investigational 616-91-1 12035
Dextromethorphan Approved 125-71-3 5362449 5360696
Hydroxocobalamin Approved 13422-51-0 5460373 44475014 11953898
Quinidine Approved, Investigational 56-54-2 441074
Menthol Approved 2216-51-5 16666

Interventional clinical trials:

(show top 50) (show all 86)

# Name Status NCT ID Phase Drugs
1 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
2 Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
3 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
4 A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB) Active, not recruiting NCT02345213 Phase 4 E2020;Placebo
5 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
6 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
7 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
8 Donepezil Treatment of Psychotic Symptoms in Dementia Patients Unknown status NCT00190021 Phase 3 donepezil
9 Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies Completed NCT00230997 Phase 3 Galantamine
10 A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase Completed NCT01278407 Phase 3 Donepezil 5 mg;Donepezil 10 mg;Donepezil matched placebo
11 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3 DatSCAN
12 Oculomotor Testing in the Differential Diagnosis of Dementia Completed NCT01577394 Phase 3
13 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
14 Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension Terminated NCT02928445 Phase 2, Phase 3 RVT-101 35 mg;RVT-101 70 mg
15 Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI) Unknown status NCT02450786 Phase 2 Donepezil
16 Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study Completed NCT02669433 Phase 2 RVT-101 35 mg;RVT-101 70 mg;Placebo
17 Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia Completed NCT02640729 Phase 2 Nelotanserin;Placebo
18 A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies Completed NCT00598650 Phase 2 E2020
19 A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431) Completed NCT00543855 Phase 2 3 mg Donepezil hydrochloride;5 mg Donepezil hydrochloride;10 mg Donepezil hydrochloride;Placebo
20 Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB) Completed NCT00630500 Phase 2 Memantine;Placebo
21 Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia Completed NCT02910102 Phase 2 RVT-101 35 mg;Placebo
22 A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET) Completed NCT01503944 Phase 1, Phase 2 18F-AV-133;18F-AV-45
23 Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Active, not recruiting NCT02702102 Phase 2 11C-PBR28
24 Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) Active, not recruiting NCT02708186 Phase 2 Nelotanserin;Placebo
25 Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder Enrolling by invitation NCT02871427 Phase 2 Nelotanserin
26 Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies Not yet recruiting NCT03467152 Phase 2 E2027;Placebo
27 Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 Completed NCT02281474 Phase 1 Nilotinib
28 Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies Recruiting NCT01340001 Phase 1
29 Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease. Unknown status NCT01876459
30 Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)) Unknown status NCT01993628
31 Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies Unknown status NCT01256905 Armodafinil
32 Gait and REM Sleep Behavior Disorder Unknown status NCT02554331
33 Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies Completed NCT00917709
34 A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease Completed NCT01944436 Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
35 Deep Brain Stimulation for Patients With Dementia With Lewy Bodies Completed NCT02263937
36 Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI) Completed NCT00820937
37 Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB) Completed NCT00776347 Donepezil;Donepezil
38 Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease Completed NCT02268617
39 A Longitudinal Multidimensional Population Study on Brain Aging Completed NCT01345110
40 Research of Biomarkers in Parkinson Disease Completed NCT00465790 Early Phase 1
41 Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach? Completed NCT00147693
42 Assessment of Social-emotional Functioning in Neurological Diseases Completed NCT01339130
43 Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues Completed NCT02610634
44 Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease Completed NCT02243982 Early Phase 1
45 Study of MRI 3Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive Atypical and Comparison to the FDG-PET Completed NCT02058043
46 Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia Completed NCT00880347
47 Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers Completed NCT00294307
49 Gait Disorders in Patients With Cognitive Decline Recruiting NCT03399591
50 Prospective Neuroimaging Investigation of Idiopathic REM Sleep Behavior Disorder Recruiting NCT02984137

Search NIH Clinical Center for Dementia, Lewy Body

Cochrane evidence based reviews: lewy body disease

Genetic Tests for Dementia, Lewy Body

Genetic tests related to Dementia, Lewy Body:

# Genetic test Affiliating Genes
1 Lewy Body Dementia 28 GBA SNCA SNCB
2 Lewy Bodies 28

Anatomical Context for Dementia, Lewy Body

MalaCards organs/tissues related to Dementia, Lewy Body:

Brain, Eye, Colon, Testes

Publications for Dementia, Lewy Body

Articles related to Dementia, Lewy Body:

(show top 50) (show all 150)
# Title Authors Year
Clinical prevalence of Lewy body dementia. ( 29448953 )
ALBA Screening Instrument (ASI): A brief screening tool for Lewy Body Dementia. ( 28088604 )
The effects of behavioral and psychological symptoms on caregiver burden in frontotemporal dementia, Lewy body dementia, and Alzheimer's disease: clinical experience in China. ( 26882509 )
GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. ( 26938614 )
Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with I^-amyloid burden and synaptic deficits in Lewy body dementias. ( 27609071 )
Patient with rapidly evolving neurological disease with neuropathological lesions of Creutzfeldt-Jakob disease, Lewy body dementia, chronic subcortical vascular encephalopathy and meningothelial meningioma. ( 27634418 )
Neuroleptic Malignant Syndrome Caused by Quetiapine in an Elderly Man with Lewy Body Dementia. ( 27564641 )
The cholinergic basal forebrain in Lewy body dementia and Alzheimer's disease. ( 25504308 )
Cognitive fluctuations in connection to dysgraphia: a comparison of Alzheimer's disease with dementia Lewy bodies. ( 25848239 )
Somatoform and Conversion Disorder Preceding Lewy Body Dementia: A Newly Described Phenomenological Manifestation of the Disease. ( 26390000 )
Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer's disease and Lewy body dementia. ( 24732348 )
Lewy body dementia: the impact on patients and caregivers. ( 25031635 )
Understanding Lewy body dementia. ( 24937845 )
Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. ( 25104558 )
Cortical changes associated with depression and antidepressant use in Alzheimer and Lewy body dementia: an MRI surface-based morphometric study. ( 23880336 )
Topiramate improves psychiatric symptoms in a patient with Lewy body dementia. ( 25539042 )
18F-FDG PET Assessment of Lewy Body Dementia with Cerebellar Diaschisis. ( 25190733 )
Function of I+-synuclein and PINK1 in Lewy body dementia (Review). ( 25355138 )
Nature and extent of person recognition impairments associated with Capgras syndrome in Lewy body dementia. ( 25309399 )
Capgras-like visual decomposition in Lewy body dementia with therapeutic response to donepezil. ( 25566416 )
Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. ( 23582751 )
Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. ( 25671083 )
Late-onset Bing-Neel syndrome associated with delirium and Lewy body dementia. ( 25413203 )
Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination. ( 24099488 )
Intrusion of rapid eye movement (REM) behavior disorder episodes into NREM sleep in a case of Lewy body dementia. ( 23063303 )
Neuropsychological Correlates of Behavioral Symptoms in Alzheimer's Disease, Frontal Variant of Frontotemporal, Subcortical Vascular, and Lewy Body Dementias: A Comparative Study. ( 24254701 )
Sympathetic skin response and heart rate variability as diagnostic tools for the differential diagnosis of Lewy body dementia and Alzheimer's disease: a diagnostic test study. ( 23457321 )
Lewy Body Dementia: The Under-Recognized but Common FOE. ( 24772233 )
Visual hallucinations treated with the reinitiation of memantine in a patient with Lewy body dementia. ( 23386073 )
Prevalence of cerebrovascular lesions in patients with Lewy body dementia: a neuropathological study. ( 23237637 )
Word list and story recall elicit different patterns of memory deficit in patients with Alzheimer's disease, frontotemporal dementia, subcortical ischemic vascular disease, and Lewy body dementia. ( 23792693 )
An effective environmental intervention for management of the 'mirror sign' in a case of probable Lewy body dementia. ( 22229711 )
Determination of the biodistribution and dosimetry of A^A^A^I-FP-CIT in male patients with suspected Parkinsonism or Lewy body dementia using planar and combined planar and SPECT/CT imaging. ( 24135637 )
Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia. ( 23124435 )
Dysphagia due to isoniazid therapy for tuberculosis in a patient with Lewy body dementia. ( 22608343 )
White matter hyperintensities in mild lewy body dementia. ( 23189084 )
Nocturnal sleep enhances working memory training in Parkinson's disease but not Lewy body dementia. ( 22907117 )
The "closing-in" phenomenon in Parkinson's disease dementia and lewy-body dementia. ( 23224479 )
Cognitive and structural magnetic resonance imaging features of Lewy body dementia and Alzheimer's disease. ( 22546353 )
Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia. ( 21353336 )
No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. ( 23069674 )
The high frequency of periodic limb movements in patients with Lewy body dementia. ( 22835911 )
Decreased oligodendrocyte nuclear diameter in Alzheimer's disease and Lewy body dementia. ( 22429607 )
Amyloid-specific T-cells differentiate Alzheimer's disease from Lewy body dementia. ( 22330173 )
Finding hope in the midst of despair: my decade with Parkinson's disease and Lewy body dementia. ( 22890610 )
Decreased I+-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. ( 21757905 )
Presenilin-2 gene mutation presenting as Lewy body dementia? ( 21409510 )
Parkinson's disease with dementia, lewy-body disorders and alpha-synuclein: recent advances and a case report. ( 21560084 )
Acid I^-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter I+-synuclein processing. ( 21472771 )
Stress and burden among caregivers of patients with Lewy body dementia. ( 20667944 )

Variations for Dementia, Lewy Body

UniProtKB/Swiss-Prot genetic disease variations for Dementia, Lewy Body:

# Symbol AA change Variation ID SNP ID
1 SNCA p.Glu46Lys VAR_022703 rs104893875

ClinVar genetic disease variations for Dementia, Lewy Body:

# Gene Variation Type Significance SNP ID Assembly Location
1 SNCA NM_000345.3(SNCA): c.157G> A (p.Ala53Thr) single nucleotide variant Pathogenic rs104893877 GRCh37 Chromosome 4, 90749300: 90749300
2 SNCA NM_000345.3(SNCA): c.136G> A (p.Glu46Lys) single nucleotide variant Pathogenic rs104893875 GRCh37 Chromosome 4, 90749321: 90749321
3 SNCA SNCA, DUPLICATION duplication Pathogenic
4 GBA NM_001005741.2(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs76763715 GRCh37 Chromosome 1, 155205634: 155205634
5 SNCB NM_001001502.2(SNCB): c.208G> A (p.Val70Met) single nucleotide variant Pathogenic rs104893936 GRCh37 Chromosome 5, 176053473: 176053473
6 SNCB NM_001001502.2(SNCB): c.368C> A (p.Pro123His) single nucleotide variant Pathogenic rs104893937 GRCh37 Chromosome 5, 176048219: 176048219

Expression for Dementia, Lewy Body

Search GEO for disease gene expression data for Dementia, Lewy Body.

Pathways for Dementia, Lewy Body

Pathways related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
6 11.76 APP CYP2D6 MAOB SLC18A2
Show member pathways
11.29 ACHE SLC6A3 TH
11 11.2 ACHE APOE CYP2D6
12 11.02 SLC18A2 SLC6A3 TH
Show member pathways
15 10.71 MAOB TH
16 10.64 PRKN RPS27A
17 10.63 ACHE TH

GO Terms for Dementia, Lewy Body

Cellular components related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.97 ACHE APP LRRK2 SNCA SNCB
2 dendrite GO:0030425 9.89 APOE LRRK2 MAPT PRNP TH
3 membrane raft GO:0045121 9.8 APP LRRK2 PARK7 PRNP SLC6A3
4 neuron projection GO:0043005 9.8 APP LRRK2 PARK7 PRKN SLC6A3 TH
5 growth cone GO:0030426 9.73 APP LRRK2 MAPT SNCA
6 presynapse GO:0098793 9.71 PARK7 PRKN SLC6A3
7 neuronal cell body GO:0043025 9.7 APOE LRRK2 MAPT SLC6A3 SNCA SNCAIP
8 terminal bouton GO:0043195 9.67 APP LRRK2 SNCA TH
9 postsynapse GO:0098794 9.65 LRRK2 PRNP SNCA
10 synaptic vesicle GO:0008021 9.65 LRRK2 SLC18A2 SNCA SNCAIP TH
11 amyloid-beta complex GO:0106003 9.56 APOE PRNP
12 nuclear envelope lumen GO:0005641 9.51 APP BCHE
13 axon GO:0030424 9.5 APP LRRK2 MAPT PARK7 SLC6A3 SNCA
14 inclusion body GO:0016234 8.92 LRRK2 PRNP SNCA SNCB
15 mitochondrion GO:0005739 10.13 CYP2D6 LRRK2 MAOB PARK7 PRKN SNCA
16 endoplasmic reticulum GO:0005783 10.12 APOE BCHE CYP2D6 LRRK2 PARK7 PRKN
17 extracellular space GO:0005615 10.11 ACHE ADAMTS2 APOE APP BCHE GBA
18 Golgi apparatus GO:0005794 10.09 ACHE APOE APP LRRK2 PRKN PRNP

Biological processes related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 9.92 APOE PARK7 PRKN SNCA SNCB
2 cellular protein metabolic process GO:0044267 9.91 APOE APP PRKN RPS27A SNCA SNCAIP
3 cellular response to oxidative stress GO:0034599 9.9 LRRK2 PARK7 SNCA
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.89 APP PARK7 SNCA
5 response to oxidative stress GO:0006979 9.89 APOE APP LRRK2 PRKN PRNP
6 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.88 GBA LRRK2 PRKN
7 mitochondrion organization GO:0007005 9.88 GBA LRRK2 PARK7 PRKN
8 positive regulation of protein binding GO:0032092 9.87 APP LRRK2 PRKN
9 learning GO:0007612 9.86 APP BCHE PRKN TH
10 regulation of autophagy GO:0010506 9.85 LRRK2 MAPT PRKN
11 adult locomotory behavior GO:0008344 9.84 APP PARK7 PRKN SNCA
12 protein destabilization GO:0031648 9.81 PRKN PRNP SNCA
13 synapse organization GO:0050808 9.78 APP MAPT SNCA SNCB
14 positive regulation of neuron death GO:1901216 9.77 MAPT PRNP SNCA
15 locomotory behavior GO:0007626 9.77 APP PRKN SLC18A2 SLC6A3 TH
16 regulation of neurotransmitter secretion GO:0046928 9.75 PRKN SNCA SNCAIP
17 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.74 LRRK2 PARK7
18 response to corticosterone GO:0051412 9.74 MAOB TH
19 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.74 LRRK2 PARK7 PRKN
20 microglial cell activation GO:0001774 9.73 MAPT SNCA
21 cellular response to dopamine GO:1903351 9.73 LRRK2 PRKN
22 locomotory exploration behavior GO:0035641 9.73 APOE LRRK2
23 supramolecular fiber organization GO:0097435 9.73 MAPT SNCA
24 cellular response to copper ion GO:0071280 9.73 PRNP SNCA
25 cellular copper ion homeostasis GO:0006878 9.72 APP PRNP
26 negative regulation of protein processing GO:0010955 9.72 LRRK2 PRNP
27 regulation of protein metabolic process GO:0051246 9.72 APOE GBA
28 amyloid precursor protein metabolic process GO:0042982 9.72 ACHE APOE
29 neurotransmitter biosynthetic process GO:0042136 9.72 ACHE SLC6A3 TH
30 negative regulation of protein phosphorylation GO:0001933 9.72 LRRK2 PARK7 PRKN PRNP SNCA
31 virion assembly GO:0019068 9.71 APOE RPS27A
32 neurotransmitter catabolic process GO:0042135 9.71 ACHE MAOB
33 positive regulation of protein metabolic process GO:0051247 9.71 APP GBA
34 regulation of dopamine metabolic process GO:0042053 9.71 PRKN SLC6A3
35 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.71 PARK7 SLC18A2
36 amyloid fibril formation GO:1990000 9.7 APP MAPT
37 monoamine transport GO:0015844 9.7 SLC18A2 SLC6A3
38 negative regulation of amyloid-beta formation GO:1902430 9.69 APOE PRNP
39 astrocyte activation GO:0048143 9.69 APP MAPT
40 dopamine biosynthetic process GO:0042416 9.69 SLC6A3 SNCA TH
41 regulation of locomotion GO:0040012 9.68 LRRK2 SNCA
42 mating behavior GO:0007617 9.68 APP TH
43 regulation of mitochondrial fission GO:0090140 9.68 LRRK2 MAPT
44 intracellular distribution of mitochondria GO:0048312 9.68 LRRK2 MAPT
45 dopamine catabolic process GO:0042420 9.67 MAOB SLC6A3
46 modulation of age-related behavioral decline GO:0090647 9.67 APP PRNP
47 positive regulation of microglial cell activation GO:1903980 9.66 APP LRRK2
48 positive regulation of autophagy of mitochondrion GO:1903599 9.66 PARK7 PRKN
49 dopamine transport GO:0015872 9.65 SLC18A2 SLC6A3
50 negative regulation of cellular protein metabolic process GO:0032269 9.65 APOE GBA

Molecular functions related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.81 LRRK2 MAPT PRNP SNCA
2 enzyme binding GO:0019899 9.7 APP BCHE MAPT PARK7 PRKN SNCA
3 copper ion binding GO:0005507 9.65 PARK7 PRNP SNCA
4 identical protein binding GO:0042802 9.65 APOE APP BCHE LRRK2 MAPT PARK7
5 amyloid-beta binding GO:0001540 9.62 ACHE APOE BCHE PRNP
6 ubiquitin-specific protease binding GO:1990381 9.57 PARK7 PRKN
7 phospholipase binding GO:0043274 9.56 PRKN SNCA
8 tubulin binding GO:0015631 9.56 LRRK2 MAPT PRKN PRNP
9 dopamine binding GO:0035240 9.55 SLC6A3 TH
10 tau protein binding GO:0048156 9.54 APOE SNCA
11 monoamine transmembrane transporter activity GO:0008504 9.49 SLC18A2 SLC6A3
12 lipoprotein particle binding GO:0071813 9.46 APOE MAPT
13 cholinesterase activity GO:0004104 9.43 ACHE BCHE
14 cupric ion binding GO:1903135 9.4 PARK7 PRNP
15 acetylcholinesterase activity GO:0003990 9.37 ACHE BCHE
16 cuprous ion binding GO:1903136 8.92 PARK7 PRNP SNCA SNCB
17 protein homodimerization activity GO:0042803 10 ACHE APOE LRRK2 MAOB MAPT PARK7

Sources for Dementia, Lewy Body

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
51 Novoseek
54 OMIM via Orphanet
58 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....